Clinical Outcomes and Prognostic Factors of Volumetric Modulated Arc Therapy (VMAT) of Esophageal Cancer

Overview

Journal Rep Pract Oncol Radiother

Date 2025 Feb 3

PMID 39895953

Authors

Tsuyoshi Fukuzawa

Ryuta Nagao

Toshihisa Kuroki

Tatsuya Mikami

Takeshi Akiba

Yoji Nakano

Yuri Toyoda

Tsuyoshi Takazawa

Yoshitsugu Matsumoto

Shigeto Kabuki

Akitomo Sugawara

Affiliations

Soon will be listed here.

Abstract

Background: The objective was to evaluate the efficacy and safety of radiotherapy and the prognostic factors in patients with esophageal cancer who received definitive radiotherapy, using volumetric modulated arc therapy (VMAT).

Materials And Methods: Forty-seven patients who received definitive radiotherapy using VMAT between September 2017 and December 2020 were enrolled. Prescription doses were 60 Gy in 30 fractions to the planning target volume (PTV) primary and 48 Gy in 30 fractions to the PTV subclinical. Overall survival (OS), progression free survival (PFS), and toxicity were analyzed, and univariate and multivariate analyses were used to investigate the prognostic factors.

Results: Median follow up time was 10 months. Most of the patients had an advanced disease stage (stage I, 12.8%; II, 8.5%; III, 27.7%; IV, 51.0%) patients (38.3%) had a T4 tumor. The median survival time was 14 months (range: 0-56 months). The 2-year OS and PFS were 31.3% and 20.4%, respectively. Acute adverse events (≥ Grade 3) were observed in 25 patients (53.2%), and the most frequent types were dysphagia, hematological toxicities including leukopenia, and febrile neutropenia in 14 (29.8%), 10 (21%), and 10 (21%) patients, respectively. Late adverse events (Grade 3 or higher) were observed in eight patients (17.0%), and the most frequent types were pneumonitis in four patients (8.5%), and Grade 5 in one patient (2.1%; esophageal fistula). In multivariate analysis, neutrophil-to-lymphocyte ratio (NLR) > 3 (p = 0.026) was significantly associated with poor survival.

Conclusion: Definitive radiotherapy of 60Gy with VMAT is feasible and safe for patients with esophageal cancer. Pre-treatment NLR >3 was an independent prognostic factor for OS.

References

Wei X, Liu H, Tucker S, Wang S, Mohan R, Cox J . Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008; 70(3):707-14. DOI: 10.1016/j.ijrobp.2007.10.056. View

Tamari K, Isohashi F, Akino Y, Suzuki O, Seo Y, Yoshioka Y . Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy. Anticancer Res. 2014; 34(12):7389-93. View

Fan X, Wang H, Mao J, Li L, Wu K . Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study. Cancer Med. 2020; 9(8):2812-2819. PMC: 7163105. DOI: 10.1002/cam4.2933. View

Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y . Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016; 115(11):1328-1334. PMC: 5129815. DOI: 10.1038/bjc.2016.350. View

Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K . Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510:.... Jpn J Clin Oncol. 2019; 49(11):1055-1060. DOI: 10.1093/jjco/hyz112. View

Byard R . Causes of sudden death related to oesophageal carcinoma. Med Sci Law. 2020; 61(1):69-72. DOI: 10.1177/0025802420962353. View

Teoh A, Chiu P, Yeung W, Liu S, Wong S, Ng E . Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol. 2012; 24(1):165-71. DOI: 10.1093/annonc/mds206. View

Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M . Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol. 2014; 88(1046):20140168. PMC: 4614235. DOI: 10.1259/bjr.20140168. View

Liu H, Wang X, Dong L, Wu Q, Liao Z, Stevens C . Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 58(4):1268-79. DOI: 10.1016/j.ijrobp.2003.09.085. View

10.

Welsh J, Seyedin S, Allen P, Hofstetter W, Ajani J, Chang J . Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2016; 12(2):375-382. DOI: 10.1016/j.jtho.2016.10.013. View

11.

Minsky B, Pajak T, Ginsberg R, Pisansky T, Martenson J, Komaki R . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20(5):1167-74. DOI: 10.1200/JCO.2002.20.5.1167. View

12.

Munch S, Aichmeier S, Hapfelmeier A, Duma M, Oechsner M, Feith M . Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol. 2016; 192(10):722-9. DOI: 10.1007/s00066-016-1020-x. View

13.

Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M . Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 2008; 92(2):266-9. DOI: 10.1016/j.radonc.2008.09.025. View

14.

Endo M, Yoshino K, Kawano T, Nagai K, Inoue H . Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2003; 13(2):125-9. DOI: 10.1046/j.1442-2050.2000.00100.x. View

15.

Uchinami Y, Myojin M, Takahashi H, Harada K, Shimizu S, Hosokawa M . Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa. Radiat Oncol. 2016; 11:84. PMC: 4915080. DOI: 10.1186/s13014-016-0660-4. View

16.

Li C, Ni W, Wang X, Zhou Z, Deng W, Chang X . A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol. 2019; 14(1):48. PMC: 6420772. DOI: 10.1186/s13014-019-1249-5. View

17.

Zhang W, Zhai T, Lu J, Chen J, Chen Z, Li D . Volumetric modulated arc therapy vs. c-IMRT for the treatment of upper thoracic esophageal cancer. PLoS One. 2015; 10(3):e0121385. PMC: 4376741. DOI: 10.1371/journal.pone.0121385. View

18.

Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M . Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009; 75(1):122-8. DOI: 10.1016/j.ijrobp.2008.10.075. View

19.

Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y . Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015; 106(4):407-12. PMC: 4409884. DOI: 10.1111/cas.12622. View

20.

Takeuchi Y, Murakami Y, Kameoka T, Ochi M, Imano N, Takahashi I . Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram. J Radiat Res. 2020; 61(2):298-306. PMC: 7246077. DOI: 10.1093/jrr/rraa001. View